Private Credit Red Flags While Axon Soars On Trump Trade
Today brought two opposite stories: private-credit withdrawal caps hit Apollo and peers, extending a steep slide, while Axon jumped over 20% as Trump’s earlier stock purchase and a potential ICE Taser deal fueled a sharp rally.
APO
What happened?
Apollo Global Management (APO) fell roughly 18% over the past week, a decline so sharp that it stands out even when you look back over the past year of trading.
Why did this happen?
On June 29, Zacks reported that Apollo and Ares once again limited withdrawals from their flagship retail-focused private-credit funds. In Apollo’s ADS fund, investors can normally only redeem up to 5% of the fund per quarter. This time, redemption requests surged to around 17%, forcing Apollo to tighten the gate.(zacks.com)
This matters for two key reasons:
-
Trust in liquidity is being questioned
These products have often been marketed as offering periodic liquidity. When investors suddenly hear “you can’t take out as much as you wanted,” they start to worry. Private credit assets are inherently hard to trade, so when too many people rush for the exit at once, the door simply isn’t wide enough. -
It’s not just one fund’s problem
The article notes that Blackstone and KKR have faced similar situations before.(zacks.com) That pushes this story from “a misstep at one manager” to “a structural stress point in the private-credit model.”
How did the market react?
- Price action: Over the past month, APO slid more than 15%, badly underperforming the broader equity market.(trefis.com)
- Peer moves: Ares (ARES), which also hit its own withdrawal limit, posted double‑digit declines over the same stretch, and large asset managers like BlackRock (BLK) traded weak in the same week.(zacks.com)
In short, the story shifted from “private credit is a growth engine” to “can I actually get my money back when markets get rough?”
What can we learn from this about the market?
-
High yields often hide structural risks
With higher interest rates and tighter bank lending, private credit has looked attractive. But many funds offered the comfort of monthly or quarterly liquidity while investing in loans that can’t be sold quickly. That mismatch doesn’t show up in a glossy marketing deck, but it becomes very real when redemptions surge. -
Fund structure news can move stocks as much as earnings
This selloff wasn’t about a surprise loss or guidance cut. It was about how capital flows in and out. Asset managers live and die not just by performance, but by asset gathering and retention. When investors question whether money is “locked in,” the stock can reprice fast.
What should investors watch next?
- Redemption queues: Do Apollo and Ares keep their limits in place next quarter? Are pending redemption requests shrinking or growing?
- Regulatory response: U.S. and European regulators may push for more disclosure and stress‑testing of semi‑liquid private funds. That could weigh on margins in the short term but help rebuild confidence over time.
- Macro and defaults: Private credit thrives on high yields, but rising default rates can quickly erase those returns. Watch economic growth and corporate default data alongside private‑credit headlines.
Why does this matter to everyday investors?
For anyone considering private-credit or alternative funds, this episode is a reminder: the key question isn’t just “What’s the yield?” but “How and when can I get my money back?”
Prospectuses often bury redemption rules and gates in the fine print. Apollo’s experience shows even blue‑chip managers may shut the gate in stress periods. The lesson is to price liquidity risk as carefully as you price return potential—and to diversify so you’re not dependent on one door staying open.
AXON
What happened?
Axon Enterprise (AXON), which makes Tasers, body cameras, and cloud software for public safety, surged over 20% in the past week, while many other defense and aerospace names drifted lower.
Why did this happen?
On June 29, multiple outlets highlighted a powerful combination of headlines:
-
Trump’s well‑timed Axon purchase
CNBC reporting, summarized by Benzinga, noted that former President Donald Trump bought between $1 million and $5 million of AXON shares on February 10, according to federal disclosures. Two weeks later, on February 24, U.S. Immigration and Customs Enforcement (ICE) posted a procurement notice seeking roughly $220 million in Tasers, cartridges, and training services.(benzinga.com)The notice doesn’t name Axon, but the specifications closely match the company’s Taser lineup. That timing—large personal stock purchase shortly before a huge potential government deal—sparked controversy and drew intense media attention.
-
Hopes for a major ICE contract
Because Axon is the dominant Taser supplier to U.S. law‑enforcement agencies, investors quickly connected the dots and started to price in the possibility of a sizeable, multi‑year ICE contract.(benzinga.com)
MarketBeat wrote that Axon shares jumped about 8.9% on Monday, trading as high as around $505, even on below‑average volume, extending a bout of volatility and headline‑driven trading.(marketbeat.com)
How did the market react?
- Single‑stock surge vs weak peers: While Axon was rallying high single digits on the day and over 20% across the week, other defense names like Northrop Grumman (NOC) and L3Harris (LHX) were down mid‑single to high‑single digits over similar periods.(marketbeat.com) This is not a broad “defense boom” move—it’s a company‑specific breakout.
- Retail buzz: On Reddit and other forums, traders noted that Axon keeps hitting new highs while getting far less attention than AI chip names or big tech, and that the Trump trade story suddenly put it “on the map” again.(reddit.com)
- Conflicting signals: Some quant‑style research earlier in June had flagged negative news sentiment and a price still below the 200‑day moving average, suggesting a downtrend.(trendmatrix.com) The Trump/ICE headlines effectively flipped that narrative in a few days.
What can we learn from this about the market?
-
Government contracts can move stocks as much as earnings
For a company that sells to law‑enforcement agencies, a single federal contract can be worth a significant slice of annual revenue. A $220 million opportunity is big enough that even the possibility of winning it can move the stock price materially. -
Politics is a volatility engine
Whether or not any rules were broken, the optics of a former president buying shares before a potentially beneficial contract are powerful. Political controversy turns into financial volatility: more media coverage → more traders paying attention → larger intraday swings. -
“Story stocks” blend long‑term fundamentals with short‑term catalysts
Axon already had a credible long‑term story—recurring software revenue from cloud evidence platforms and AI‑assisted tools on top of hardware sales.(investor.axon.com) The Trump/ICE angle adds a short‑term spark, pulling in momentum traders who might not have cared about the fundamentals a month ago.
What should investors watch next?
- Did Axon actually win the ICE contract?
The procurement notice only opens the bidding. The crucial follow‑ups are: Does Axon secure the award, what’s the exact dollar value, and over how many years? - Regulatory and ethics fallout: Will ethics watchdogs or Congress investigate the timing of Trump’s trades? If so, does that chill Axon’s future federal business or just create more headlines?
- Volatility and position sizing: After a move this sharp, the stock can easily overshoot in both directions. Investors should be clear on whether they’re in for the long‑term public‑safety digitization theme or just riding a short‑term political wave.
Why does this matter to everyday investors?
Axon’s week shows that big moves don’t always come from earnings reports. Policy, procurement, and politics can be just as powerful. For individual investors, that means:
- Don’t ignore “boring” contract and disclosure headlines—they can be early clues to major stock moves.
- Separate the durable part of the story (recurring revenue, product moat) from one‑off catalysts (a single contract, a political personality).
Axon’s 7‑day surge is a classic case of a company‑specific catalyst pushing a stock far ahead of its sector peers, reminding us to look past sector averages and into the details of what’s driving each name.
This content is for informational purposes only and does not constitute a recommendation to invest in any specific security or asset.